Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 200

1.

Combining the serum pepsinogen level and Helicobacter pylori antibody test for predicting the histology of gastric neoplasm.

Choi HS, Lee SY, Kim JH, Sung IK, Park HS, Shim CS, Jin CJ.

J Dig Dis. 2014 Jun;15(6):293-8. doi: 10.1111/1751-2980.12144.

PMID:
24602176
2.

The new modified ABCD method for gastric neoplasm screening.

Park CH, Kim EH, Jung da H, Chung H, Park JC, Shin SK, Lee SK, Lee YC.

Gastric Cancer. 2016 Jan;19(1):128-35. doi: 10.1007/s10120-015-0473-4.

PMID:
25663259
3.
5.

Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer.

Yoshida T, Kato J, Inoue I, Yoshimura N, Deguchi H, Mukoubayashi C, Oka M, Watanabe M, Enomoto S, Niwa T, Maekita T, Iguchi M, Tamai H, Utsunomiya H, Yamamichi N, Fujishiro M, Iwane M, Takeshita T, Ushijima T, Ichinose M.

Int J Cancer. 2014 Mar 15;134(6):1445-57. doi: 10.1002/ijc.28470.

6.

Advanced method for evaluation of gastric cancer risk by serum markers: determination of true low-risk subjects for gastric neoplasm.

Boda T, Ito M, Yoshihara M, Kitamura Y, Matsuo T, Oka S, Tanaka S, Chayama K.

Helicobacter. 2014 Feb;19(1):1-8. doi: 10.1111/hel.12101.

PMID:
24215601
7.

Relationship between Helicobacter pylori status and serum pepsinogens as serologic markers in atrophic gastritis.

Bölükbaş C, Bölükbaş FF, Ovünç O, Kiliç G, Dalay R, Güven H, Uras F, Yardimci TK, Sökmen MH, Agan AF, Pişkinpaşa N.

Turk J Gastroenterol. 2006 Sep;17(3):172-6.

8.

Fasting gastric pH of Japanese subjects stratified by IgG concentration against Helicobacter pylori and pepsinogen status.

Kishikawa H, Nishida J, Ichikawa H, Kaida S, Takarabe S, Matsukubo T, Miura S, Morishita T, Hibi T.

Helicobacter. 2011 Dec;16(6):427-33. doi: 10.1111/j.1523-5378.2011.00868.x.

PMID:
22059393
9.

Prevalence of Helicobacter pylori infection and atrophic gastritis in Latvia.

Leja M, Cine E, Rudzite D, Vilkoite I, Huttunen T, Daugule I, Rumba-Rozenfelde I, Pimanov S, Liepniece-Karele I, Pahomova J, Purmalis K, Eglitis J, Pirags V, Dzerve V, Erglis A.

Eur J Gastroenterol Hepatol. 2012 Dec;24(12):1410-7. doi: 10.1097/MEG.0b013e3283583ca5.

PMID:
23114744
10.

Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study.

Watabe H, Mitsushima T, Yamaji Y, Okamoto M, Wada R, Kokubo T, Doi H, Yoshida H, Kawabe T, Omata M.

Gut. 2005 Jun;54(6):764-8.

11.

Two distinct aetiologies of cardia cancer; evidence from premorbid serological markers of gastric atrophy and Helicobacter pylori status.

Hansen S, Vollset SE, Derakhshan MH, Fyfe V, Melby KK, Aase S, Jellum E, McColl KE.

Gut. 2007 Jul;56(7):918-25.

12.

Development of gastric cancer in nonatrophic stomach with highly active inflammation identified by serum levels of pepsinogen and Helicobacter pylori antibody together with endoscopic rugal hyperplastic gastritis.

Watanabe M, Kato J, Inoue I, Yoshimura N, Yoshida T, Mukoubayashi C, Deguchi H, Enomoto S, Ueda K, Maekita T, Iguchi M, Tamai H, Utsunomiya H, Yamamichi N, Fujishiro M, Iwane M, Tekeshita T, Mohara O, Ushijima T, Ichinose M.

Int J Cancer. 2012 Dec 1;131(11):2632-42. doi: 10.1002/ijc.27514.

13.

Serum pepsinogen and Helicobacter pylori infection--a Japanese population study.

Toyoda K, Furusyo N, Ihara T, Ikezaki H, Urita Y, Hayashi J.

Eur J Clin Microbiol Infect Dis. 2012 Sep;31(9):2117-24. doi: 10.1007/s10096-011-1543-0.

PMID:
22354521
15.

Inverse background of Helicobacter pylori antibody and pepsinogen in reflux oesophagitis compared with gastric cancer: analysis of 5732 Japanese subjects.

Yamaji Y, Mitsushima T, Ikuma H, Okamoto M, Yoshida H, Kawabe T, Shiratori Y, Saito K, Yokouchi K, Omata M.

Gut. 2001 Sep;49(3):335-40.

16.

Serum pepsinogen II is a better diagnostic marker in gastric cancer.

Cao XY, Jia ZF, Jin MS, Cao DH, Kong F, Suo J, Jiang J.

World J Gastroenterol. 2012 Dec 28;18(48):7357-61. doi: 10.3748/wjg.v18.i48.7357.

17.

Effect of Helicobacter pylori infection combined with CagA and pepsinogen status on gastric cancer development among Japanese men and women: a nested case-control study.

Sasazuki S, Inoue M, Iwasaki M, Otani T, Yamamoto S, Ikeda S, Hanaoka T, Tsugane S; Japan Public Health Center Study Group..

Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1341-7.

18.

[Relationship between pepsinogen I/II ratio and age or upper gastrointestinal diseases in Helicobacter pylori-positive and -negative subjects].

Paik CN, Chung IS, Nam KW, Kwon JH, Chang JH, Suh JP, Park JM, Cho YK, Lee IS, Kim SW, Choi MG.

Korean J Gastroenterol. 2007 Aug;50(2):84-91. Korean.

19.

Analysis of ABC (D) stratification for screening patients with gastric cancer.

Kudo T, Kakizaki S, Sohara N, Onozato Y, Okamura S, Inui Y, Mori M.

World J Gastroenterol. 2011 Nov 21;17(43):4793-8. doi: 10.3748/wjg.v17.i43.4793.

20.

Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study.

Väänänen H, Vauhkonen M, Helske T, Kääriäinen I, Rasmussen M, Tunturi-Hihnala H, Koskenpato J, Sotka M, Turunen M, Sandström R, Ristikankare M, Jussila A, Sipponen P.

Eur J Gastroenterol Hepatol. 2003 Aug;15(8):885-91.

PMID:
12867799
Items per page

Supplemental Content

Support Center